Welcome to Lantibio

Located in Chapel Hill, North Carolina, Lantibio is a development stage biotechnology company dedicated to the discovery, development and commercialization of effective treatments for ocular and pulmonary disease.

This first of the company’s two lead compounds, Moli1901, promotes the hydration of epithelial tissue.  An ophthalmic solution of Moli1901 is currently entering Phase II clinical development in the United States for the treatment of dry eye syndrome. Formulated for aerosol delivery, Moli1901 is in Phase II clinical development in Europe for the treatment of cystic fibrosis (CF) under a development and marketing license with AOP Orphan Pharmaceuticals AG in Vienna, Austria.

.

For more information about Moli1901 for the treatment of dry eye syndrome, please visit Dry Eye Syndrome.

For more information about Moli1901 for the treatment of CF, please visit Cystic Fibrosis.

The second lead compound, VISMED® , is currently marketed in Europe under a CE mark. VISMED® is a patented formulation of sodium hyaluronate approved for the use as a lubricant eye drop. In addition, initial clinical trials in Europe have shown VISMED® to be a promising treatment for Dry Eye Syndrome. VISMED® has been licensed by Lantibio from TRB Chemedica  for development and marketing in the U.S.

For more information about TRB Chemedica , please visit Press Releases.

For more information about VISMED® for the treatment of dry eye syndrome, please visit Dry Eye Syndrome and Business Development.

The gene encoding the Moli1901 molecule has been isolated and sequenced, clearing the way for the generation of analogs of the molecule. Such a library of compounds will support a robust and dynamic pipeline of drug candidates for development or out-licensing by Lantibio.

For more information about the library of Moli1901-related compounds, please visit Library of Polypeptides and Business Development.

Two free radical scavengers, designed as Moli56A and Moli56B, are part of the pipeline of promising proprietary technologies. The compounds offer potential benefit in the management of life-threatening organ failure.

For more information about the library of Moli1901-related compounds, please visit Free Radical Scavengers and Business Development.